This Neutropenia Biologic Drug Treatment market report provides a comprehensive analysis of the market’s characteristics, size, and growth, including segmentation, regional and country-level breakdowns, competitive landscape, market shares, trends, and strategies. It also tracks historical and forecasted market growth across various geographies.
The neutropenia biologic drug treatment market size has grown strongly in recent years. It will grow from $13.22 billion in 2024 to $14.08 billion in 2025 at a compound annual growth rate (CAGR) of 6.5%. The growth in the historic period can be attributed to market access and reimbursement, patient advocacy and awareness, physician education and training, biologic drug development, clinical trial success.
The neutropenia biologic drug treatment market size is expected to see strong growth in the next few years. It will grow to $18.1 billion in 2029 at a compound annual growth rate (CAGR) of 6.5%. The growth in the forecast period can be attributed to healthcare cost management, patient-centric care models, combination therapies development, regulatory changes and approvals, personalized medicine approaches. Major trends in the forecast period include global market accessibility, advancements in manufacturing techniques, treatment protocol streamlining, biosimilar adoption, development of long-acting formulations.
The increase in global cancer cases is expected to contribute to the expansion of the neutropenia biologic drugs market. The growing incidence of cancer, coupled with a rise in individuals undergoing chemotherapy, has led to an increased prevalence of neutropenia. For example, as of January 2022, the American Cancer Society projected approximately 1.9 million new cancer diagnoses and 609,360 cancer-related deaths in the US, averaging around 1,670 fatalities per day. Lung, prostate, bowel, and female breast cancer collectively represent 43 percent of all new cancer cases worldwide. Consequently, the surge in global cancer incidence rates is anticipated to drive demand for neutropenia biologic drug treatment in the coming years.
Government initiatives aimed at research and development in healthcare are poised to propel the Neutropenia biologic drug treatment market's growth. These initiatives encompass specific actions, programs, policies, or projects undertaken by government authorities at different levels (local, regional, national, or international) to address specific issues, achieve defined goals, or bring about positive changes in society. Various government bodies are launching healthcare initiatives to support different facets, including neutropenia biologic drug treatment. As an illustration, in 2022, the UK government, through the Department of Health and Social Care, announced a funding commitment of £260 million (US $270.65 million) to boost healthcare research and manufacturing. This allocation by BEIS and DHSC is intended to support NHS-led health research in diagnostics and treatment through new privacy-preserving platforms and clinical research services. Additionally, £60 million (US $63.6 million) was earmarked to facilitate the expansion of life sciences manufacturing in the UK.
Leading companies in the neutropenia biologic drug treatment sector are focusing on developing biosimilars to provide more affordable alternatives to existing biologics. Biosimilars are biologic medications designed to be nearly identical to an already approved reference biologic, exhibiting no significant differences in safety or effectiveness. For example, in May 2023, Amneal Pharmaceuticals, a US-based pharmaceutical company, launched Fylnetra (pegfilgrastim-pbbk), a biosimilar to Neulasta, which is intended to treat and prevent febrile neutropenia in patients undergoing chemotherapy. This biosimilar binds to specific receptors on hematopoietic cells, stimulating the proliferation and differentiation of neutrophil precursors in the bone marrow. Consequently, it enhances the production of neutrophils, which are vital for combating infections, especially in patients receiving myelosuppressive chemotherapy, thus reducing the occurrence of febrile neutropenia related to cancer treatments.
Major players in the neutropenia biologic drug treatment market are focusing on the development of innovative biosimilars, such as pegfilgrastim-pbbk (Fylnetra), to drive market revenues. For instance, in May 2023, Amneal Pharmaceuticals Inc. launched Fylnetra, a biosimilar referencing Neulasta and approved by the Food and Drug Administration (FDA) for the treatment of neutropenia. Fylnetra is available in a convenient pre-filled single-dose syringe.
In November 2022, Biocon Biologics, specializing in the development of biological drugs, acquired Viatris, a US-based company known for developing neutropenia biologic drugs such as pegfilgrastim. This acquisition further strengthens Biocon Biologics' capabilities in research and development, global-scale manufacturing, and commercialization in emerging markets within the biosimilars sector.
Neutropenia biologic drug treatment involves the use of medications aimed at reducing fevers, preventing potential infections, and stimulating bone marrow activity to enhance neutrophil production. Neutropenia, characterized by a deficiency of neutrophils, a specific type of white blood cell, necessitates such interventions.
The primary drugs utilized in neutropenia biologic drug treatment include filgrastim, pegfilgrastim, lenograstim, lipegfilgrastim, and sargramostim. Filgrastim, a synthetic version of granulocyte colony-stimulating protein, is administered through injections to elevate neutrophil production following chemotherapy. Various types of treatments encompass antibiotic drugs, granulocyte-colony-stimulating factor (G-CSF), antifungal drugs, among others. These medications are accessible through diverse channels, including retail pharmacies, hospital pharmacies, and online pharmacies.
The neutropenia biologic drug treatment market research report is one of a series of new reports that provides neutropenia biologic drug treatment market statistics, including global market size, regional shares, competitors with a neutropenia biologic drug treatment market share, detailed neutropenia biologic drug treatment market segments, market trends and opportunities, and any further data you may need to thrive in the neutropenia biologic drug treatment industry. This neutropenia biologic drug treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
Major companies operating in the neutropenia biologic drug treatment market include Amgen Inc., Pfizer Inc., Novartis AG, Teva Pharmaceutical Industries Ltd., Sanofi S.A., GlaxoSmithKline plc, F. Hoffmann-La Roche Ltd, Merck & Co. Inc., Johnson & Johnson, Baxter International Inc., Mylan N.V., Celgene Corporation, Biogen Inc., AbbVie Inc., Regeneron Pharmaceuticals Inc., AstraZeneca plc, Eli Lilly and Company, Takeda Pharmaceutical Company Limited, Bayer AG, Sun Pharmaceutical Industries Ltd., Lupin Limited, Fresenius SE & Co. KGaA, Gilead Sciences Inc., Daiichi Sankyo Company, Kyowa Kirin Co. Ltd., CSL Limited, Dr. Reddy's Laboratories Ltd., Bristol-Myers Squibb Company, Astellas Pharma Inc., Otsuka Pharmaceutical Co. Ltd.
North America was the largest region in the neutropenia biologic drug treatment market in 2024. The regions covered in the neutropenia biologic drug treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the neutropenia biologic drug treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The neutropenia biologic drug treatment market consists of sales of cefepime, ceftazidime, piperacillin-tazobactam, and meropenem. Values in this market are 'factory gate values', that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
The neutropenia biologic drug treatment market size has grown strongly in recent years. It will grow from $13.22 billion in 2024 to $14.08 billion in 2025 at a compound annual growth rate (CAGR) of 6.5%. The growth in the historic period can be attributed to market access and reimbursement, patient advocacy and awareness, physician education and training, biologic drug development, clinical trial success.
The neutropenia biologic drug treatment market size is expected to see strong growth in the next few years. It will grow to $18.1 billion in 2029 at a compound annual growth rate (CAGR) of 6.5%. The growth in the forecast period can be attributed to healthcare cost management, patient-centric care models, combination therapies development, regulatory changes and approvals, personalized medicine approaches. Major trends in the forecast period include global market accessibility, advancements in manufacturing techniques, treatment protocol streamlining, biosimilar adoption, development of long-acting formulations.
The increase in global cancer cases is expected to contribute to the expansion of the neutropenia biologic drugs market. The growing incidence of cancer, coupled with a rise in individuals undergoing chemotherapy, has led to an increased prevalence of neutropenia. For example, as of January 2022, the American Cancer Society projected approximately 1.9 million new cancer diagnoses and 609,360 cancer-related deaths in the US, averaging around 1,670 fatalities per day. Lung, prostate, bowel, and female breast cancer collectively represent 43 percent of all new cancer cases worldwide. Consequently, the surge in global cancer incidence rates is anticipated to drive demand for neutropenia biologic drug treatment in the coming years.
Government initiatives aimed at research and development in healthcare are poised to propel the Neutropenia biologic drug treatment market's growth. These initiatives encompass specific actions, programs, policies, or projects undertaken by government authorities at different levels (local, regional, national, or international) to address specific issues, achieve defined goals, or bring about positive changes in society. Various government bodies are launching healthcare initiatives to support different facets, including neutropenia biologic drug treatment. As an illustration, in 2022, the UK government, through the Department of Health and Social Care, announced a funding commitment of £260 million (US $270.65 million) to boost healthcare research and manufacturing. This allocation by BEIS and DHSC is intended to support NHS-led health research in diagnostics and treatment through new privacy-preserving platforms and clinical research services. Additionally, £60 million (US $63.6 million) was earmarked to facilitate the expansion of life sciences manufacturing in the UK.
Leading companies in the neutropenia biologic drug treatment sector are focusing on developing biosimilars to provide more affordable alternatives to existing biologics. Biosimilars are biologic medications designed to be nearly identical to an already approved reference biologic, exhibiting no significant differences in safety or effectiveness. For example, in May 2023, Amneal Pharmaceuticals, a US-based pharmaceutical company, launched Fylnetra (pegfilgrastim-pbbk), a biosimilar to Neulasta, which is intended to treat and prevent febrile neutropenia in patients undergoing chemotherapy. This biosimilar binds to specific receptors on hematopoietic cells, stimulating the proliferation and differentiation of neutrophil precursors in the bone marrow. Consequently, it enhances the production of neutrophils, which are vital for combating infections, especially in patients receiving myelosuppressive chemotherapy, thus reducing the occurrence of febrile neutropenia related to cancer treatments.
Major players in the neutropenia biologic drug treatment market are focusing on the development of innovative biosimilars, such as pegfilgrastim-pbbk (Fylnetra), to drive market revenues. For instance, in May 2023, Amneal Pharmaceuticals Inc. launched Fylnetra, a biosimilar referencing Neulasta and approved by the Food and Drug Administration (FDA) for the treatment of neutropenia. Fylnetra is available in a convenient pre-filled single-dose syringe.
In November 2022, Biocon Biologics, specializing in the development of biological drugs, acquired Viatris, a US-based company known for developing neutropenia biologic drugs such as pegfilgrastim. This acquisition further strengthens Biocon Biologics' capabilities in research and development, global-scale manufacturing, and commercialization in emerging markets within the biosimilars sector.
Neutropenia biologic drug treatment involves the use of medications aimed at reducing fevers, preventing potential infections, and stimulating bone marrow activity to enhance neutrophil production. Neutropenia, characterized by a deficiency of neutrophils, a specific type of white blood cell, necessitates such interventions.
The primary drugs utilized in neutropenia biologic drug treatment include filgrastim, pegfilgrastim, lenograstim, lipegfilgrastim, and sargramostim. Filgrastim, a synthetic version of granulocyte colony-stimulating protein, is administered through injections to elevate neutrophil production following chemotherapy. Various types of treatments encompass antibiotic drugs, granulocyte-colony-stimulating factor (G-CSF), antifungal drugs, among others. These medications are accessible through diverse channels, including retail pharmacies, hospital pharmacies, and online pharmacies.
The neutropenia biologic drug treatment market research report is one of a series of new reports that provides neutropenia biologic drug treatment market statistics, including global market size, regional shares, competitors with a neutropenia biologic drug treatment market share, detailed neutropenia biologic drug treatment market segments, market trends and opportunities, and any further data you may need to thrive in the neutropenia biologic drug treatment industry. This neutropenia biologic drug treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
Major companies operating in the neutropenia biologic drug treatment market include Amgen Inc., Pfizer Inc., Novartis AG, Teva Pharmaceutical Industries Ltd., Sanofi S.A., GlaxoSmithKline plc, F. Hoffmann-La Roche Ltd, Merck & Co. Inc., Johnson & Johnson, Baxter International Inc., Mylan N.V., Celgene Corporation, Biogen Inc., AbbVie Inc., Regeneron Pharmaceuticals Inc., AstraZeneca plc, Eli Lilly and Company, Takeda Pharmaceutical Company Limited, Bayer AG, Sun Pharmaceutical Industries Ltd., Lupin Limited, Fresenius SE & Co. KGaA, Gilead Sciences Inc., Daiichi Sankyo Company, Kyowa Kirin Co. Ltd., CSL Limited, Dr. Reddy's Laboratories Ltd., Bristol-Myers Squibb Company, Astellas Pharma Inc., Otsuka Pharmaceutical Co. Ltd.
North America was the largest region in the neutropenia biologic drug treatment market in 2024. The regions covered in the neutropenia biologic drug treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the neutropenia biologic drug treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The neutropenia biologic drug treatment market consists of sales of cefepime, ceftazidime, piperacillin-tazobactam, and meropenem. Values in this market are 'factory gate values', that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. Neutropenia Biologic Drug Treatment Market Characteristics3. Neutropenia Biologic Drug Treatment Market Trends and Strategies4. Neutropenia Biologic Drug Treatment Market - Macro Economic Scenario Including the Impact of Interest Rates, Inflation, Geopolitics, and the Recovery from COVID-19 on the Market32. Global Neutropenia Biologic Drug Treatment Market Competitive Benchmarking and Dashboard33. Key Mergers and Acquisitions in the Neutropenia Biologic Drug Treatment Market34. Recent Developments in the Neutropenia Biologic Drug Treatment Market
5. Global Neutropenia Biologic Drug Treatment Growth Analysis and Strategic Analysis Framework
6. Neutropenia Biologic Drug Treatment Market Segmentation
7. Neutropenia Biologic Drug Treatment Market Regional and Country Analysis
8. Asia-Pacific Neutropenia Biologic Drug Treatment Market
9. China Neutropenia Biologic Drug Treatment Market
10. India Neutropenia Biologic Drug Treatment Market
11. Japan Neutropenia Biologic Drug Treatment Market
12. Australia Neutropenia Biologic Drug Treatment Market
13. Indonesia Neutropenia Biologic Drug Treatment Market
14. South Korea Neutropenia Biologic Drug Treatment Market
15. Western Europe Neutropenia Biologic Drug Treatment Market
16. UK Neutropenia Biologic Drug Treatment Market
17. Germany Neutropenia Biologic Drug Treatment Market
18. France Neutropenia Biologic Drug Treatment Market
19. Italy Neutropenia Biologic Drug Treatment Market
20. Spain Neutropenia Biologic Drug Treatment Market
21. Eastern Europe Neutropenia Biologic Drug Treatment Market
22. Russia Neutropenia Biologic Drug Treatment Market
23. North America Neutropenia Biologic Drug Treatment Market
24. USA Neutropenia Biologic Drug Treatment Market
25. Canada Neutropenia Biologic Drug Treatment Market
26. South America Neutropenia Biologic Drug Treatment Market
27. Brazil Neutropenia Biologic Drug Treatment Market
28. Middle East Neutropenia Biologic Drug Treatment Market
29. Africa Neutropenia Biologic Drug Treatment Market
30. Neutropenia Biologic Drug Treatment Market Competitive Landscape and Company Profiles
31. Neutropenia Biologic Drug Treatment Market Other Major and Innovative Companies
35. Neutropenia Biologic Drug Treatment Market High Potential Countries, Segments and Strategies
36. Appendix
Executive Summary
Neutropenia Biologic Drug Treatment Global Market Report 2025 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on neutropenia biologic drug treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for neutropenia biologic drug treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The neutropenia biologic drug treatment market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include: the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:
1) By Drug Type: Filgrastim; Pegfilgrastim; Lenograstim; Lipegfilgrastim; Sargramostim2) By Treatment Type: Antibiotic Drugs; Granulocyte-Colony-Stimulating Factor (G-CSF); Antifungal Drugs; Other Treatment Types
3) By Distribution Channel: Retail Pharmacies; Hospital Pharmacies; Online Pharmacies
Subsegments:
1) By Filgrastim: Brand Name Examples: Neupogen; Indications and Usage2) By Pegfilgrastim: Brand Name Examples: Neulasta; Indications and Usage
3) By Lenograstim: Brand Name Examples: Granocyte; Indications and Usage
4) By Lipegfilgrastim: Brand Name Examples: Lonquex; Indications and Usage
5) By Sargramostim: Brand Name Examples: Leukine; Indications and Usage
Key Companies Mentioned: Amgen Inc.; Pfizer Inc.; Novartis AG; Teva Pharmaceutical Industries Ltd.; Sanofi S.a.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Companies Mentioned
The major companies featured in this Neutropenia Biologic Drug Treatment market report include:- Amgen Inc.
- Pfizer Inc.
- Novartis AG
- Teva Pharmaceutical Industries Ltd.
- Sanofi S.A.
- GlaxoSmithKline plc
- F. Hoffmann-La Roche Ltd
- Merck & Co. Inc.
- Johnson & Johnson
- Baxter International Inc.
- Mylan N.V.
- Celgene Corporation
- Biogen Inc.
- AbbVie Inc.
- Regeneron Pharmaceuticals Inc.
- AstraZeneca plc
- Eli Lilly and Company
- Takeda Pharmaceutical Company Limited
- Bayer AG
- Sun Pharmaceutical Industries Ltd.
- Lupin Limited
- Fresenius SE & Co. KGaA
- Gilead Sciences Inc.
- Daiichi Sankyo Company
- Kyowa Kirin Co. Ltd.
- CSL Limited
- Dr. Reddy's Laboratories Ltd.
- Bristol-Myers Squibb Company
- Astellas Pharma Inc.
- Otsuka Pharmaceutical Co. Ltd.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 175 |
| Published | April 2025 |
| Forecast Period | 2025 - 2029 |
| Estimated Market Value ( USD | $ 14.08 Billion |
| Forecasted Market Value ( USD | $ 18.1 Billion |
| Compound Annual Growth Rate | 6.5% |
| Regions Covered | Global |
| No. of Companies Mentioned | 31 |
